Atomo Diagnostics Appoints Interim Chair Amid Board Changes

Atomo Diagnostics Ltd. ( (AU:AT1) ) has issued an update.

Atomo Diagnostics Limited has appointed its current CEO and Managing Director, Mr. John Kelly, as the Interim Chair of the Board following recent changes in the Board’s composition. This move is intended to maintain continuity and stability in the company’s leadership. The Board is committed to strong corporate governance and plans to appoint a permanent independent Chair in the future. Mr. Kelly’s remuneration will remain unchanged, and shareholders will be kept informed of further updates.

More about Atomo Diagnostics Ltd.

Atomo is an Australian-headquartered medical device company that supplies unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market. Their patented devices simplify testing procedures, enhance usability, and improve reliability for rapid point-of-care and at-home testing applications. The company has commercialized products internationally, with supply agreements for testing applications targeting infectious diseases like HIV, Active Syphilis, and viral vs bacterial differentiation, as well as early pregnancy detection.

Average Trading Volume: 505,773

Technical Sentiment Signal: Sell

Current Market Cap: A$10.98M

For an in-depth examination of AT1 stock, go to TipRanks’ Stock Analysis page.